Form 4: Annovis Bio Director Boosts Stake with Share Purchases

Annovis Bio Director Michael B. Hoffman acquired 18,645 shares of common stock through multiple transactions.

Summary

• Michael B. Hoffman, a Director of Annovis Bio, Inc. (ANVS), acquired a total of 18,645 shares of common stock on August 19, 2025.
• The acquisitions were made in four separate transactions at prices ranging from $2.57 to $2.60 per share.
• Specifically, 6,717 shares were acquired at $2.60, 5,283 shares at $2.59, 5,545 shares at $2.58, and 1,100 shares at $2.57.
• Following these transactions, Michael B. Hoffman directly beneficially owns 1,464,929 shares of Annovis Bio common stock.
• Additionally, 223,357 shares are indirectly beneficially owned through The 2018 Jane and Michael Hoffman Descendants Trust, over which Mr. Hoffman has voting and investment power.

Sentiment

Score: 8

Explanation: The sentiment is positive due to significant insider buying by a director, indicating strong confidence in the company's future performance and valuation at the current price levels.

Positives

• Insider buying by a Director signals confidence in the company's future prospects and valuation.
• The acquisition of 18,645 shares represents a notable increase in the director's direct holdings.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance, as it is a transaction report.

Industry Context

This insider transaction is specific to Annovis Bio and does not directly reflect broader industry trends, though insider confidence can be a positive signal within the biotechnology sector, which often relies on investor sentiment regarding pipeline development and clinical trial success.

Related Party Transactions

• 223,357 shares are indirectly held by The 2018 Jane and Michael Hoffman Descendants Trust, over which the reporting person, Michael B. Hoffman, has voting and investment power.

Stakeholder Impact

• Shareholders may view this insider buying as a positive indicator of future stock performance, potentially increasing investor confidence.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates

Recommendation

The significant insider buying by a director, Michael B. Hoffman, suggests strong conviction in Annovis Bio's current valuation and future prospects. Such actions by insiders are often interpreted as a bullish signal, indicating that those with the most intimate knowledge of the company believe the stock is undervalued or poised for growth. This direct investment aligns the director's interests more closely with shareholders and could precede positive operational or clinical developments.

Keywords

Annovis Bio, ANVS, Insider Buying, Director Stock Purchase, SEC Form 4, Biotechnology, Pharmaceuticals, Stock Acquisition